Treatment of endocrine resistant metastatic breast cancer in the era of antibody drug conjugates.

Autor:	Heater NK; Department of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Franco S; Department of Hematology and Oncology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA., Shah A; Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, IL, USA.
Jazyk:	angličtina
Zdroj:	Annals of translational medicine [Ann Transl Med] 2023 Oct 25; Vol. 11 (11), pp. 399. Date of Electronic Publication: 2023 Feb 27.
DOI:	10.21037/atm-23-314
Abstrakt:	Competing Interests: Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-23-314/coif). AS reports participation in an advisory board from AstraZeneca and Gilead and payment for this service. The other authors have no conflicts of interest to declare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu